文献速递冠心病血脂与心血管预防

IMPROVE-IT:急性冠脉综合征后依折麦布加他汀可减少缺血性卒中

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
PubMed 文献 · Circulation · 2017-09-30

IMPROVE-IT试验中,急性冠脉综合征患者随机接受依折麦布/辛伐他汀或安慰剂/辛伐他汀,中位随访6年。依折麦布组首次缺血性卒中显著降低21%,总卒中事件亦显著减少;随机化前有卒中史者绝对风险降低8.6%。

要点

  • 依折麦布加辛伐他汀使首次缺血性卒中风险显著降低21%。
  • 包括复发事件在内的总卒中风险亦显著降低。
  • 随机化前有卒中史者获益更大,绝对风险降低8.6%。

核心结论

  • 急性冠脉综合征稳定后,在辛伐他汀基础上加用依折麦布可减少缺血性卒中发生,尤其对既往有卒中史者效果显著。

研究设计与样本

  • IMPROVE-IT试验将急性冠脉综合征患者随机分配至安慰剂/辛伐他汀或依折麦布/辛伐他汀组,中位随访6年。

主要发现

  • 依折麦布/辛伐他汀组首次任何病因卒中风险非显著降低(4.2% vs 4.8%;HR 0.86;95%CI 0.73-1.00;P=0.052)。
  • 首次缺血性卒中显著降低21%(3.4% vs 4.1%;HR 0.79;95%CI 0.67-0.94;P=0.008)。
  • 总卒中事件分析中,任何病因卒中(HR 0.83;95%CI 0.70-0.98;P=0.029)和缺血性卒中(HR 0.76;95%CI 0.63-0.91;P=0.003)均显著减少。
  • 随机化前有卒中史者,任何病因卒中绝对风险降低8.6%(10.2% vs 18.8%;NNT=12;HR 0.60;95%CI 0.38-0.95;P=0.030),缺血性卒中绝对风险降低7.6%(8.7% vs 16.3%;NNT=13;HR 0.52;95%CI 0.31-0.86;P=0.011)。

关键数值与推荐

  • 首次任何病因卒中HR 0.86(95%CI 0.73-1.00;P=0.052)。
  • 首次缺血性卒中HR 0.79(95%CI 0.67-0.94;P=0.008)。
  • 总任何病因卒中HR 0.83(95%CI 0.70-0.98;P=0.029)。
  • 总缺血性卒中HR 0.76(95%CI 0.63-0.91;P=0.003)。
  • 既往卒中者任何病因卒中HR 0.60(95%CI 0.38-0.95;P=0.030),NNT=12。

临床怎么用

  • 急性冠脉综合征后稳定患者,可考虑在辛伐他汀基础上加用依折麦布以降低缺血性卒中风险。
  • 对既往有卒中史的患者,加用依折麦布的绝对获益更大,应优先考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), with a focus on patients with a stroke before randomization. METHODS: Patients who experienced acute coronary syndrome were randomized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followed for a median of 6 years. Treatment efficacy was assessed for the entire population and by subgroups for the first and total (first and subsequent) events for the end points of stroke of any etiology, stroke subtypes, and the primary trial end point at 7 years. RESULTS: Of 18 144 patients, 641 (3.5%) experienced at least 1 stroke; most were ischemic (527, 82%). Independent predictors of stroke included prior stroke, older age, atrial fibrillation, congestive heart failure, diabetes mellitus, myocardial infarction, and renal dysfunction. There was a nonsignificant reduction in the first event of stroke of any etiology (4.2% versus 4.8%; hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.73-1.00; P=0.052) with ezetimibe/simvastatin versus placebo/simvastatin, driven by a significant 21% reduction in ischemic stroke (3.4% versus 4.1%; HR, 0.79; 95% CI, 0.67-0.94; P=0.008) and a nonsignificant increase in hemorrhagic stroke (0.8% versus 0.6%; HR, 1.38; 95% CI, 0.93-2.04; P=0.11). Evaluating total events, including the first and all recurrent strokes, ezetimibe/simvastatin reduced stroke of any etiology (HR, 0.83; 95% CI, 0.70-0.98; P=0.029) and ischemic stroke (HR, 0.76; 95% CI, 0.63-0.91; P=0.003). Patients who had experienced a stroke prior to randomization were at a higher risk of recurrence and demonstrated an absolute risk reduction of 8.6% for stroke of any etiology (10.2% versus 18.8%; number needed to treat=12; HR, 0.60; 95% CI, 0.38-0.95; P=0.030) and 7.6% for ischemic stroke (8.7% versus 16.3%; number needed to treat=13; HR, 0.52; 95% CI, 0.31-0.86; P=0.011) with ezetimibe added to simvastatin therapy. CONCLUSIONS: The addition of ezetimibe to simvastatin in patients stabilized after acute coronary syndrome reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00202878.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bohula EA, Wiviott SD, Giugliano RP, et al. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017. PMID: 28972004. doi:10.1161/CIRCULATIONAHA.117.029095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。